The SEC charged Hong (John) Wang and his company, Precision Clinical Consulting LLC, with insider trading in the stock of C4 Therapeutics, Inc., a clinical stage biopharmaceutical company after becoming aware of positive clinical trial results for C4’s flagship multiple myeloma and non-Hodgkin lymphoma drug while performing biostatistical consulting work for the company and had access to the drug’s clinical trial data. Wang allegedly made $489,739 in realized and unrealized profits from his position, purchasing C4 shares through four separate brokerage accounts, including one in the name of Precision. The SEC case is being litigated, and the U.S. Attorney’s Office for the District of Massachusetts announced parallel criminal charges against Wang.